baclofen has been researched along with Ache in 143 studies
Excerpt | Relevance | Reference |
---|---|---|
"To assess attainment of individual treatment goals one year after intrathecal baclofen (ITB) pump implantation in individuals with dyskinetic cerebral palsy (CP)." | 9.69 | Attainment of personal goals in the first year of intrathecal baclofen treatment in dyskinetic cerebral palsy: a prospective cohort study. ( Becher, JG; Bonouvrié, LA; Buizer, AI; Haberfehlner, H; Vermeulen, RJ; Vles, JSH, 2023) |
"Background and Purpose- Intrathecal baclofen (ITB) is an effective treatment for managing patients with severe poststroke spasticity, who can experience continued pain and decline in their quality of life (QoL)." | 9.27 | Effect of Intrathecal Baclofen on Pain and Quality of Life in Poststroke Spasticity. ( Abouihia, A; Calabrese, A; Cloud, G; Creamer, M; Francisco, GE; Kossmehl, P; Saltuari, L; Ward, AB; Wissel, J; Yochelson, M; Zampolini, M, 2018) |
") baclofen on chronic, dysesthetic, and spasm-related pain (SRP) among patients with spinal spasticity [i." | 9.07 | Intrathecal baclofen suppresses central pain in patients with spinal lesions. A pilot study. ( D'Luzansky, SC; Herman, RM; Ippolito, R, 1992) |
"We describe a unique case of intrathecal baclofen overdose mimicking brainstem death, during bilateral anterior cingulate cortex deep brain stimulation (DBS) for pain." | 8.12 | Intrathecal baclofen overdose mimicking brainstem death during deep brain stimulation surgery for pain. ( Alamri, A; Aziz, T; Mostofi, A; Pereira, E, 2022) |
"Intrathecal baclofen (ITB) pumps used to manage spasticity in children with cerebral palsy (CP) also improve pain outcomes for some but not all patients." | 7.96 | Investigating the Feasibility of a Modified Quantitative Sensory Testing Approach to Profile Sensory Function and Predict Pain Outcomes Following Intrathecal Baclofen Implant Surgery in Cerebral Palsy. ( Barney, CC; Merbler, AM; Simone, DA; Symons, FJ; Walk, D, 2020) |
"To investigate the effect of intrathecal baclofen (ITB) on function and activity in dyskinetic cerebral palsy (CP)." | 7.88 | Intrathecal baclofen in dyskinetic cerebral palsy: effects on function and activity. ( Askljung, B; Corneliusson, O; Eek, MN; Himmelmann, K; Lindh, K; Olsson, K; Påhlman, M, 2018) |
"To compare spasticity levels, pain, sleep, fatigue, and quality of life between individuals receiving treatment with intrathecal versus oral baclofen." | 7.83 | Intrathecal Versus Oral Baclofen: A Matched Cohort Study of Spasticity, Pain, Sleep, Fatigue, and Quality of Life. ( Binler, D; Chu, SK; Lee, J; Marciniak, C; Mathur, SN; McCormick, ZL; Neudorf, D, 2016) |
"We describe a patient in whom long-term, therapeutic infusion of the selective gamma-amino-butyric acid type B (GABAB) receptor agonist, baclofen, into the cerebrospinal fluid (CSF) gave rise to three distinct varieties of memory impairment: i) repeated, short periods of severe global amnesia, ii) accelerated long-term forgetting (ALF), evident over intervals of days and iii) a loss of established autobiographical memories." | 7.83 | The GABAB receptor agonist, baclofen, contributes to three distinct varieties of amnesia in the human brain - A detailed case report. ( Carr, M; Dewar, M; Hoefeijzers, S; Milton, F; Streatfield, C; Zeman, A, 2016) |
" Our aims were to investigate the effect and mechanism of action of the GABA(B) receptor agonist, baclofen, on gastric hypersensitivity in a validated rat model of functional dyspepsia (FD)." | 7.77 | The analgesic effects of the GABAB receptor agonist, baclofen, in a rodent model of functional dyspepsia. ( Liu, LS; Pasricha, PJ; Shenoy, M, 2011) |
"Baclofen, a specific GABA(B) receptor agonist, is used to treat spasticity and its off-label use includes the treatment of pain." | 7.75 | Role of GABA(B) receptor agonist baclofen in acute pain modulation during the early postnatal period. ( Franek, M; Vaculin, S, 2009) |
"Seven cases of combination of intrathecal (IT) ziconotide and baclofen therapy in patients with refractory neuropathic pain and spasticity were reviewed." | 7.75 | Intrathecal ziconotide and baclofen provide pain relief in seven patients with neuropathic pain and spasticity: case reports. ( Burton, AW; Danyo, DA; Frost, S; Glanzer, J; Saulino, M; Solanki, DR, 2009) |
"Prospective studies that address both efficacy and safety of continuous infusion of intrathecal baclofen (CITB) in children with spastic cerebral palsy (CP), and that use outcome measures beyond muscle tone are lacking." | 7.75 | Safety and one-year efficacy of intrathecal baclofen therapy in children with intractable spastic cerebral palsy. ( Gorter, JW; Hoving, MA; Spincemaille, GH; van Kleef, M; van Kranen-Mastenbroek, VH; van Raak, EP; Vles, JS, 2009) |
"We report on the case of a patient suffering from Friedreich's ataxia (FA) with very painful and disabling spasms that were improved markedly by intrathecal baclofen infusion." | 7.73 | Intrathecal baclofen in the treatment of painful, disabling spasms in Friedreich's ataxia. ( Ben Smail, D; Bussel, B; Denys, P; Jacq, C, 2005) |
"We report the treatment of severe neuropathic pain in a patient with ED and the combined intrathecal application of baclofen and morphine in 5 patients with severe spasticity related pain." | 7.71 | Combined intrathecal baclofen and morphine infusion for the treatment of spasticity related pain and central deafferentiation pain. ( Becker, R; Bertalanffy, H; Gatscher, S; Uhle, E, 2002) |
"In this case study we describe a dual approach to the palliation of difficult muscle spasms using intrathecal baclofen via a fully implanted system, together with the homeopathic approach to symptom control." | 7.70 | Intrathecal baclofen and homeopathy for the treatment of painful muscle spasms associated with malignant spinal cord compression. ( Hicks, F; Thompson, E, 1998) |
"Baclofen, an agonist of the gamma-aminobutyric acid (GABA) receptor, has antinociceptive effects, and its intrathecal administration reduces allodynic responses in animal models of neurogenic central pain." | 7.69 | A new approach to control central deafferentation pain: spinal intrathecal baclofen. ( Iseki, H; Kawabatake, H; Kawamura, H; Taira, T; Takakura, K; Tanikawa, T, 1995) |
"We investigated the short-term effects of an intrathecal bolus injection of baclofen on central pain due to stroke or spinal cord injury." | 7.69 | A new approach to the control of central deafferentation pain--spinal intrathecal baclofen. ( Iseki, H; Kawabatake, H; Kawamura, H; Taira, T; Takakura, K; Tanikawa, T; Ueda, A, 1995) |
"The mean daily dosage alleviating spasticity on the hemiparetic side-without affecting the nonparetic side-was 119 microg/day (range 50 to 360 microg/day)." | 6.74 | Limitations of intrathecal baclofen for spastic hemiparesis following stroke. ( Kofler, M; Quirbach, E; Saltuari, L; Schauer, R; Singer, M, 2009) |
"Clinical signs and symptoms of spasticity include hypertonia, involuntary movements (spasms, clonus), decreased range of motion, contractures, and often spasm-related pain." | 6.73 | Intrathecal baclofen for spasticity-related pain in amyotrophic lateral sclerosis: efficacy and factors associated with pain relief. ( Bethoux, FA; Boulis, NM; Gogol, DM; Harrison, M; McClelland, S; Pioro, EP; Schwetz, KM; Stough, DK; Sutliff, MH, 2008) |
"Sporadic cases of dramatic recovery from persistent vegetative state after intrathecal administration of baclofen have been reported." | 6.44 | Intrathecal baclofen in the treatment of post-stroke central pain, dystonia, and persistent vegetative state. ( Hori, T; Taira, T, 2007) |
"Baclofen is also used for control of dystonia due to cerebral palsy or reflex sympathetic dystrophy." | 6.42 | Clinical application of drug pump for spasticity, pain, and restorative neurosurgery: other clinical applications of intrathecal baclofen. ( Hori, T; Taira, T, 2003) |
"To assess attainment of individual treatment goals one year after intrathecal baclofen (ITB) pump implantation in individuals with dyskinetic cerebral palsy (CP)." | 5.69 | Attainment of personal goals in the first year of intrathecal baclofen treatment in dyskinetic cerebral palsy: a prospective cohort study. ( Becher, JG; Bonouvrié, LA; Buizer, AI; Haberfehlner, H; Vermeulen, RJ; Vles, JSH, 2023) |
"The treatment of spasticity and dystonia in these patients is difficult partly due to the relentless nature of this progressive disorder." | 5.48 | Intrathecal baclofen treatment an option in X-linked adrenoleukodystrophy. ( Ehrstedt, C; Hjartarson, HT; Tedroff, K, 2018) |
"Background and Purpose- Intrathecal baclofen (ITB) is an effective treatment for managing patients with severe poststroke spasticity, who can experience continued pain and decline in their quality of life (QoL)." | 5.27 | Effect of Intrathecal Baclofen on Pain and Quality of Life in Poststroke Spasticity. ( Abouihia, A; Calabrese, A; Cloud, G; Creamer, M; Francisco, GE; Kossmehl, P; Saltuari, L; Ward, AB; Wissel, J; Yochelson, M; Zampolini, M, 2018) |
"To determine the impact of intrathecal baclofen (ITB) therapy on outcomes of functional independence, pain, subjective improvement, performance, and standard measures of spasticity." | 5.11 | A clinical study of intrathecal baclofen using a programmable pump for intractable spasticity. ( Guillaume, D; Roeste, G; Van Havenbergh, A; Vidal, J; Vloeberghs, M, 2005) |
") baclofen on chronic, dysesthetic, and spasm-related pain (SRP) among patients with spinal spasticity [i." | 5.07 | Intrathecal baclofen suppresses central pain in patients with spinal lesions. A pilot study. ( D'Luzansky, SC; Herman, RM; Ippolito, R, 1992) |
"This study evaluated the analgesic efficacy of baclofen in relation to specific pain stimuli in 83 women (27 nulliparas and 56 multiparas) undergoing voluntary abortion (clamping of the cervix and dilatation and curettage)." | 5.05 | Double-blind placebo-controlled trial of baclofen, alone and in combination, in patients undergoing voluntary abortion. ( Bacchini, M; Battagliarin, G; Brambilla, C; Corli, O; Di Piazza, D; Grossi, E; Roma, G, 1984) |
"Ziconotide is a nonopioid intrathecal analgesic used to manage moderate to severe chronic pain." | 4.86 | Ziconotide combination intrathecal therapy: rationale and evidence. ( Deer, T; Rauck, RL; Wallace, MS, 2010) |
" To date, only the antidepressants and the anticonvulsants have shown any effectiveness, albeit incomplete and inconsistent, and many questions remain unanswered: What are the exact indications for the antidepressants? What component of neuropathic pain do they relieve, and through which mechanisms? Which type of antidepressants should be prescribed? A first-generation tricyclic? Or a new compound with a selective action on serotonin reuptake? What are the effective dosage and duration of the treatment? What is it mechanism of action? What other antalgic effects do carbamazepine and baclofen possess apart from their action on trigeminal neuralgia? The opiates are generally considered to be without effect, but recent clinical and experimental findings seem to point otherwise." | 4.78 | [Pharmacological treatment of neuropathic pain]. ( Ollat, H, 1992) |
"We describe a unique case of intrathecal baclofen overdose mimicking brainstem death, during bilateral anterior cingulate cortex deep brain stimulation (DBS) for pain." | 4.12 | Intrathecal baclofen overdose mimicking brainstem death during deep brain stimulation surgery for pain. ( Alamri, A; Aziz, T; Mostofi, A; Pereira, E, 2022) |
"Intrathecal baclofen (ITB) pumps used to manage spasticity in children with cerebral palsy (CP) also improve pain outcomes for some but not all patients." | 3.96 | Investigating the Feasibility of a Modified Quantitative Sensory Testing Approach to Profile Sensory Function and Predict Pain Outcomes Following Intrathecal Baclofen Implant Surgery in Cerebral Palsy. ( Barney, CC; Merbler, AM; Simone, DA; Symons, FJ; Walk, D, 2020) |
"To investigate the effect of intrathecal baclofen (ITB) on function and activity in dyskinetic cerebral palsy (CP)." | 3.88 | Intrathecal baclofen in dyskinetic cerebral palsy: effects on function and activity. ( Askljung, B; Corneliusson, O; Eek, MN; Himmelmann, K; Lindh, K; Olsson, K; Påhlman, M, 2018) |
"We describe a patient in whom long-term, therapeutic infusion of the selective gamma-amino-butyric acid type B (GABAB) receptor agonist, baclofen, into the cerebrospinal fluid (CSF) gave rise to three distinct varieties of memory impairment: i) repeated, short periods of severe global amnesia, ii) accelerated long-term forgetting (ALF), evident over intervals of days and iii) a loss of established autobiographical memories." | 3.83 | The GABAB receptor agonist, baclofen, contributes to three distinct varieties of amnesia in the human brain - A detailed case report. ( Carr, M; Dewar, M; Hoefeijzers, S; Milton, F; Streatfield, C; Zeman, A, 2016) |
"To compare spasticity levels, pain, sleep, fatigue, and quality of life between individuals receiving treatment with intrathecal versus oral baclofen." | 3.83 | Intrathecal Versus Oral Baclofen: A Matched Cohort Study of Spasticity, Pain, Sleep, Fatigue, and Quality of Life. ( Binler, D; Chu, SK; Lee, J; Marciniak, C; Mathur, SN; McCormick, ZL; Neudorf, D, 2016) |
"The following, from the 12th OESO World Conference: Cancers of the Esophagus, includes commentaries on the role for ketamine and other alternative treatments in esophageal disorders; the use of linaclotide in the treatment of esophageal pain; the alginate test as a diagnostic criterion in gastroesophageal reflux disease (GERD); the use of baclofen in treatment of GERD; the effects of opioids on the esophagus; the use of antagonists on the receptor level in GERD; the effect of local formulation of drugs on the esophageal mucosa; and the use of electroencephalographic fingerprints to predict the effect of pharmacological treatment." | 3.80 | Pharmacologic treatments for esophageal disorders. ( Blackshaw, LA; Bordin, DS; Brock, C; Brokjaer, A; Drewes, AM; Farmer, AD; Krarup, AL; Lottrup, C; Masharova, AA; Moawad, FJ; Olesen, AE, 2014) |
" Systemic administration of 1 reduced acetic acid-induced writhing, the inflammatory phase of formalin-induced pain, and capsaicin-induced mechanical allodynia." | 3.79 | Antiallodynic and analgesic effects of maslinic acid, a pentacyclic triterpenoid from Olea europaea. ( Baeyens, JM; Cobos, EJ; Entrena, JM; García-Granados, A; Nieto, FR; Parra, A, 2013) |
" Our aims were to investigate the effect and mechanism of action of the GABA(B) receptor agonist, baclofen, on gastric hypersensitivity in a validated rat model of functional dyspepsia (FD)." | 3.77 | The analgesic effects of the GABAB receptor agonist, baclofen, in a rodent model of functional dyspepsia. ( Liu, LS; Pasricha, PJ; Shenoy, M, 2011) |
"Prospective studies that address both efficacy and safety of continuous infusion of intrathecal baclofen (CITB) in children with spastic cerebral palsy (CP), and that use outcome measures beyond muscle tone are lacking." | 3.75 | Safety and one-year efficacy of intrathecal baclofen therapy in children with intractable spastic cerebral palsy. ( Gorter, JW; Hoving, MA; Spincemaille, GH; van Kleef, M; van Kranen-Mastenbroek, VH; van Raak, EP; Vles, JS, 2009) |
"Seven cases of combination of intrathecal (IT) ziconotide and baclofen therapy in patients with refractory neuropathic pain and spasticity were reviewed." | 3.75 | Intrathecal ziconotide and baclofen provide pain relief in seven patients with neuropathic pain and spasticity: case reports. ( Burton, AW; Danyo, DA; Frost, S; Glanzer, J; Saulino, M; Solanki, DR, 2009) |
"Baclofen, a specific GABA(B) receptor agonist, is used to treat spasticity and its off-label use includes the treatment of pain." | 3.75 | Role of GABA(B) receptor agonist baclofen in acute pain modulation during the early postnatal period. ( Franek, M; Vaculin, S, 2009) |
"We report on the case of a patient suffering from Friedreich's ataxia (FA) with very painful and disabling spasms that were improved markedly by intrathecal baclofen infusion." | 3.73 | Intrathecal baclofen in the treatment of painful, disabling spasms in Friedreich's ataxia. ( Ben Smail, D; Bussel, B; Denys, P; Jacq, C, 2005) |
"The good clinical response to treatment of spasticity and rigidity, improved quality of life, pain reduction and patient satisfaction with short length of admission demonstrate the efficacy of intrathecal baclofen therapy." | 3.73 | Continuous intrathecal baclofen administration by a fully implantable electronic pump for severe spasticity treatment: our experience. ( Bucolo, GE; Castiglione, A; Fazzio, S; Guglielmino, A; Mangiameli, S; Patti, F; Pittalà, G; Sorbello, M; Zingale, SF, 2006) |
"A selective GABA(B) receptor agonist, baclofen, is known to suppress neuropathic pain." | 3.72 | Activaton of GABAB receptor inhibits the excitability of rat small diameter trigeminal root ganglion neurons. ( Ikeda, M; Kadoi, J; Matsumoto, S; Takeda, M; Tanimoto, T, 2004) |
"We report the treatment of severe neuropathic pain in a patient with ED and the combined intrathecal application of baclofen and morphine in 5 patients with severe spasticity related pain." | 3.71 | Combined intrathecal baclofen and morphine infusion for the treatment of spasticity related pain and central deafferentiation pain. ( Becker, R; Bertalanffy, H; Gatscher, S; Uhle, E, 2002) |
" In vivo microdialysis was performed in parallel in awake, freely moving rats in order to evaluate possible alterations in extracellular gamma-aminobutyric acid (GABA) levels in a pain-modulating region, the medial thalamus." | 3.70 | Tiagabine antinociception in rodents depends on GABA(B) receptor activation: parallel antinociception testing and medial thalamus GABA microdialysis. ( Bartolini, A; Ipponi, A; Lamberti, C; Malmberg-Aiello, P; Medica, A, 1999) |
"In this case study we describe a dual approach to the palliation of difficult muscle spasms using intrathecal baclofen via a fully implanted system, together with the homeopathic approach to symptom control." | 3.70 | Intrathecal baclofen and homeopathy for the treatment of painful muscle spasms associated with malignant spinal cord compression. ( Hicks, F; Thompson, E, 1998) |
"The present study was designed to investigate the effect of a selective GABA(B) receptor agonist baclofen on the pain-like nociceptive behavior (scratching, biting and licking) induced by intrathecal (i." | 3.70 | Modulation of NMDA- and (+)TAN-67-induced nociception by GABA(B) receptors in the mouse spinal cord. ( Imai, S; Kamei, J; Nagase, H; Narita, M; Suzuki, T; Tsuda, M; Yajima, Y, 2000) |
"The present data suggest that intrathecal morphine, and to some extent clonidine, but not baclofen, alleviated the abnormal pain-related behaviors in this new rat model of partial peripheral nerve injury." | 3.70 | Effects of intrathecal morphine, clonidine and baclofen on allodynia after partial sciatic nerve injury in the rat. ( Hao, JX; Wiesenfeld-Hallin, Z; Xu, IS; Xu, XJ, 1999) |
"Intrathecal administration of baclofen, a GABA(B)-receptor agonist, affects pain behavior induced by formalin in a biphasic manner; baclofen at low doses enhances pain while producing antinociception at high doses." | 3.70 | Presynaptic inhibition by baclofen of miniature EPSCs and IPSCs in substantia gelatinosa neurons of the adult rat spinal dorsal horn. ( Iyadomi, I; Iyadomi, M; Kumamoto, E; Tomokuni, K; Yoshimura, M, 2000) |
"Experimental studies indicate that the effects of spinal cord stimulation (SCS) on 'hypersymptoms' in neuropathic pain conditions may at least partly be mediated via GABAergic and adenosine-dependent mechanisms." | 3.69 | Modulation of spinal pain mechanisms by spinal cord stimulation and the potential role of adjuvant pharmacotherapy. ( Cui, JG; Linderoth, B; Meyerson, BA; O'Connor, WT; Segerdahl, M; Sollevi, A; Stiller, CO; Yakhnitsa, V, 1997) |
"We investigated the short-term effects of an intrathecal bolus injection of baclofen on central pain due to stroke or spinal cord injury." | 3.69 | A new approach to the control of central deafferentation pain--spinal intrathecal baclofen. ( Iseki, H; Kawabatake, H; Kawamura, H; Taira, T; Takakura, K; Tanikawa, T; Ueda, A, 1995) |
"In this pharmacological study we have assessed the effect of baclofen, a selective GABAB receptor agonist, on spinal expression of the immediate early gene c-Fos and the peripheral oedema evoked by a prolonged peripheral inflammation due to intraplantar carrageenan." | 3.69 | The contribution of GABAB receptor-mediated events to inflammatory pain processing: carrageenan oedema and associated spinal c-Fos expression in the rat. ( Besson, JM; Buritova, J; Chapman, V; Honoré, P, 1996) |
"Baclofen, an agonist of the gamma-aminobutyric acid (GABA) receptor, has antinociceptive effects, and its intrathecal administration reduces allodynic responses in animal models of neurogenic central pain." | 3.69 | A new approach to control central deafferentation pain: spinal intrathecal baclofen. ( Iseki, H; Kawabatake, H; Kawamura, H; Taira, T; Takakura, K; Tanikawa, T, 1995) |
"The present study was designed to characterise the analgesia produced by the GABA B agonist baclofen in tonic pain in monkeys." | 3.68 | GABA B mediated analgesia in tonic pain in monkeys. ( Mathur, R; Nayar, U; Sharma, R, 1993) |
" The results showed that baclofen, substance P (SP) and naloxone administered intrathecally could reduce the tail pressure pain threshold." | 3.67 | Further evidence for possible analgesic mechanism of electroacupuncture: effects on neuropeptides and serotonergic neurons in rat spinal cord. ( Inoki, R; Lin, JG; Tsai, HY, 1989) |
" The 5-HT released from the spinal cord was significantly increased by somatostatin, substance P and peripheral pain stimulation (tail pinch), but not affected by neurotensin, beta-endorphin and met-enkephalin." | 3.67 | Effect of neuroactive peptides on labeled 5-hydroxytryptamine release from rat spinal cord. ( Tsai, HY, 1984) |
"The influence of spasticity, experienced by the patients with a spinal cord injury, on their quality of life was analyzed before the surgery and 12 months after it." | 3.30 | Neuromodulation and quality of life for patient with spasticity after spinal cord injury. ( Biktimirov, A; Bryukhovetskiy, I; Sharma, A; Sharma, HS, 2023) |
"The mean daily dosage alleviating spasticity on the hemiparetic side-without affecting the nonparetic side-was 119 microg/day (range 50 to 360 microg/day)." | 2.74 | Limitations of intrathecal baclofen for spastic hemiparesis following stroke. ( Kofler, M; Quirbach, E; Saltuari, L; Schauer, R; Singer, M, 2009) |
" The chronic use of this drug in a pump however proved to be technically problematic and all the adenosine cases were eventually terminated." | 2.73 | Drug-enhanced spinal stimulation for pain: a new strategy. ( Lind, G; Linderoth, B; Schechtmann, G; Winter, J, 2007) |
"Clinical signs and symptoms of spasticity include hypertonia, involuntary movements (spasms, clonus), decreased range of motion, contractures, and often spasm-related pain." | 2.73 | Intrathecal baclofen for spasticity-related pain in amyotrophic lateral sclerosis: efficacy and factors associated with pain relief. ( Bethoux, FA; Boulis, NM; Gogol, DM; Harrison, M; McClelland, S; Pioro, EP; Schwetz, KM; Stough, DK; Sutliff, MH, 2008) |
"Pain is one of the most common symptoms in children and young people (CYP) with life-limiting conditions (LLCs) which include a wide range of diagnoses including cancer." | 2.52 | Pharmacological interventions for pain in children and adolescents with life-limiting conditions. ( Beecham, E; Bluebond-Langner, M; Candy, B; Howard, R; Jones, L; Laddie, J; McCulloch, R; Rees, H; Vickerstaff, V, 2015) |
"Of all drug use to treat MS symptoms, treatment for pain accounts for nearly 30 % of total use." | 2.49 | Pain and multiple sclerosis: pathophysiology and treatment. ( Messmer Uccelli, M; Solaro, C; Trabucco, E, 2013) |
"These include the management of dystonia and chronic neuropathic pain." | 2.44 | Intrathecal baclofen therapy for neurological disorders: a sound knowledge base but many challenges remain. ( Brennan, PM; Whittle, IR, 2008) |
"Sporadic cases of dramatic recovery from persistent vegetative state after intrathecal administration of baclofen have been reported." | 2.44 | Intrathecal baclofen in the treatment of post-stroke central pain, dystonia, and persistent vegetative state. ( Hori, T; Taira, T, 2007) |
"Baclofen is also used for control of dystonia due to cerebral palsy or reflex sympathetic dystrophy." | 2.42 | Clinical application of drug pump for spasticity, pain, and restorative neurosurgery: other clinical applications of intrathecal baclofen. ( Hori, T; Taira, T, 2003) |
"Undertreatment of pain is a persistent clinical problem for patients with cancer." | 2.41 | [Non-opioid analgesics in cancer pain]. ( Dohi, S, 2001) |
"Among the more common symptoms is spasticity." | 2.41 | Management of spasticity, pain, and paroxysmal phenomena in multiple sclerosis. ( Schapiro, RT, 2001) |
"Pain is a common feature of spasticity and muscle spasms and the reasons for this are discussed in this article." | 2.41 | The management of pain in spasticity. ( Kadies, M; Ward, AB, 2002) |
"They have been of value in treating pain of cancer and spasticity through spinal subarachnoid catheters." | 2.37 | Drug pumps for treatment of neurologic diseases and pain. ( Penn, RD, 1985) |
"Baclofen was weaned down and switched to intrathecal ziconotide at 0." | 1.51 | Low-Dose Intrathecal Ziconotide for Spasticity From Primary Lateral Sclerosis: A Case Report. ( Goldstein, RB; Kohan, LR; Zhu, X, 2019) |
"The treatment of spasticity and dystonia in these patients is difficult partly due to the relentless nature of this progressive disorder." | 1.48 | Intrathecal baclofen treatment an option in X-linked adrenoleukodystrophy. ( Ehrstedt, C; Hjartarson, HT; Tedroff, K, 2018) |
"The prevalence of idiopathic vulvodynia and proctodynia is high." | 1.40 | Vulvodynia and proctodynia treated with topical baclofen 5 % and palmitoylethanolamide. ( Keppel Hesselink, JM; Kopsky, DJ; Sajben, NL, 2014) |
"Pain affects quality of life, functional status, cognition, mood, sleep, and well-being." | 1.36 | Persistent non-cancer pain management in the older adult. ( Javier, N; Tomas, M, 2010) |
"In trials to preserve the pharmacological profile and improve the bioavailability via lipophilicity increment of baclofen 1 and searching for more potent and less toxic muscle relaxants and analgesics, nine substituted cyclic analogues of 1 were designed and synthesized." | 1.35 | 5-(4-Chlorophenyl)-5,6-dihydro-1,3-oxazepin-7(4H)-one derivatives as lipophilic cyclic analogues of baclofen: design, synthesis, and neuropharmacological evaluation. ( Abdel-Hafez, AA; Abdel-Wahab, BA, 2008) |
"Treatment of spasticity with intrathecal baclofen pump implantation is a chance for clinical improvement in patients with severe spasticity." | 1.34 | [The parents expectations after baclofen pump implantation in child with severe spasticity in physical rehabilitation and psychological aspects]. ( Fafara, A; Grzegorzewski, P; Kawecka, J; Kawecki, Z; Kwiatkowski, S, 2007) |
"A well known drug in the treatment of spasticity is the GABA(B) agonist Baclofen." | 1.31 | Baclofen inhibits ANP-mediated cyclic GMP synthesis in the rat cervical spinal cord. ( de Louw, AJ; de Vente, J; Steinbusch, HP; Steinbusch, HW; Troost, J; Vles, JS, 2002) |
"These data also suggest that the hyperalgesia produced by high doses of baclofen does not result from disinhibition of a serotonergic pain facilitatory pathway, but rather from direct inhibition of tonically-active pain inhibitory neurons in the NRM and NGCpalpha." | 1.30 | Intrathecal methysergide antagonizes the antinociception, but not the hyperalgesia produced by microinjection of baclofen in the ventromedial medulla of the rat. ( Hammond, DL; Nelson, V; Thomas, DA, 1998) |
"Diabetic animals displayed marked mechanical hyperalgesia, and some thermal hypoalgesia." | 1.30 | Critical evaluation of the streptozotocin model of painful diabetic neuropathy in the rat. ( Eastwood, C; Fox, A; Gentry, C; Manning, D; Urban, L, 1999) |
"]) did not change tail-flick latency in control animals but produced a dose-dependent enhancement of the antinociception induced by clonidine and morphine, and shifted their dose-response curves to the left." | 1.29 | Cromakalim differentially enhances antinociception induced by agonists of alpha(2)adrenoceptors, gamma-aminobutyric acid(B), mu and kappa opioid receptors. ( Baeyens, JM; Barrios, M; Ocaña, M, 1996) |
"When baclofen was administered intraperitoneally, pretreatment with depletors of monoamines and catecholamines (reserpine, alpha-MPT) produced a marked increase in antinociceptive activity in both tests." | 1.27 | Monoamines as mediators of the antinociceptive effect of baclofen. ( Sawynok, J, 1983) |
"D-Baclofen should prove to be a useful tool for investigation of the role of stereoselective baclofen receptors in a variety of pharmacological processes." | 1.27 | D-Baclofen: is it an antagonist at baclofen receptors? ( Dickson, C; Sawynok, J, 1984) |
"D-Baclofen is an antagonist at spinal baclofen receptors." | 1.27 | GABAergic mechanisms in antinociception. ( Sawynok, J, 1984) |
"Clonidine pretreatment did not significantly alter the effect of baclofen alone, but reversed the potentiation of the action of baclofen produced by both theophylline and isobutylmethylxanthine." | 1.27 | Clonidine reverses methylxanthine-induced potentiation of baclofen antinociception. ( Sawynok, J; Steardo, L, 1985) |
"Both baclofen and clonidine were injected intraperitoneally in all experiments." | 1.27 | Role of ascending and descending noradrenergic pathways in the antinociceptive effect of baclofen and clonidine. ( Reid, A; Sawynok, J, 1986) |
"The main indication was incapacitating spasticity resistant to oral treatment with baclofen and caused by spinal cord injury or lesion (11 patients), multiple sclerosis (11 patients), infantile cerebral palsy (3 patients) and cerebral injury, hypoxia or ischaemia (5 patients)." | 1.27 | Implanted pump systems for treatment of spasticity. ( Dralle, D; Müller, H; Wurdinger, T; Zierski, J, 1988) |
"Acute encephalopathy and an abnormal electroencephalogram with a periodic sharp wave pattern developed in a 58-year-old woman shortly after she received a few doses of baclofen." | 1.27 | Periodic sharp waves in baclofen-induced encephalopathy. ( Benarroch, EE; Hormes, JT; Klass, DW; Rodriguez, M, 1988) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 24 (16.78) | 18.7374 |
1990's | 34 (23.78) | 18.2507 |
2000's | 47 (32.87) | 29.6817 |
2010's | 33 (23.08) | 24.3611 |
2020's | 5 (3.50) | 2.80 |
Authors | Studies |
---|---|
Abdel-Hafez, AA | 1 |
Abdel-Wahab, BA | 1 |
Nieto, FR | 1 |
Cobos, EJ | 1 |
Entrena, JM | 1 |
Parra, A | 1 |
García-Granados, A | 1 |
Baeyens, JM | 3 |
Bonouvrié, LA | 1 |
Haberfehlner, H | 1 |
Becher, JG | 1 |
Vles, JSH | 1 |
Vermeulen, RJ | 1 |
Buizer, AI | 1 |
Alamri, A | 1 |
Mostofi, A | 1 |
Aziz, T | 1 |
Pereira, E | 1 |
Stone, SN | 1 |
Wei, D | 1 |
Reger, C | 1 |
Biktimirov, A | 1 |
Bryukhovetskiy, I | 1 |
Sharma, A | 1 |
Sharma, HS | 1 |
Quallo, T | 1 |
Alkhatib, O | 1 |
Gentry, C | 3 |
Andersson, DA | 1 |
Bevan, S | 1 |
Hjartarson, HT | 1 |
Ehrstedt, C | 1 |
Tedroff, K | 1 |
Eek, MN | 1 |
Olsson, K | 1 |
Lindh, K | 1 |
Askljung, B | 1 |
Påhlman, M | 1 |
Corneliusson, O | 1 |
Himmelmann, K | 1 |
Kalyvas, AV | 1 |
Drosos, E | 1 |
Korfias, S | 1 |
Gatzonis, S | 1 |
Themistocleous, M | 1 |
Sakas, DE | 1 |
Creamer, M | 1 |
Cloud, G | 1 |
Kossmehl, P | 1 |
Yochelson, M | 1 |
Francisco, GE | 1 |
Ward, AB | 2 |
Wissel, J | 1 |
Zampolini, M | 1 |
Abouihia, A | 1 |
Calabrese, A | 1 |
Saltuari, L | 2 |
Sriperumbuduri, S | 1 |
Hiremath, S | 1 |
Platt, L | 1 |
Deboer, SR | 1 |
Shenderov, K | 1 |
Probasco, JC | 1 |
Guterman, EL | 1 |
Manesh, R | 1 |
Sperati, CJ | 1 |
Berntsson, SG | 1 |
Gauffin, H | 1 |
Melberg, A | 1 |
Holtz, A | 1 |
Landtblom, AM | 1 |
Zhu, X | 1 |
Kohan, LR | 1 |
Goldstein, RB | 1 |
Barney, CC | 1 |
Merbler, AM | 1 |
Simone, DA | 1 |
Walk, D | 1 |
Symons, FJ | 1 |
Hatem, SM | 1 |
Minooee, K | 1 |
Haviv, Y | 1 |
Zadik, Y | 1 |
Sharav, Y | 1 |
Benoliel, R | 1 |
Keppel Hesselink, JM | 1 |
Kopsky, DJ | 1 |
Sajben, NL | 1 |
Scherkenbach, LA | 1 |
Coles, LD | 1 |
Patterson, EE | 1 |
Cloyd, JC | 1 |
Krach, LE | 1 |
Kriel, RL | 1 |
Blackshaw, LA | 1 |
Bordin, DS | 1 |
Brock, C | 1 |
Brokjaer, A | 1 |
Drewes, AM | 1 |
Farmer, AD | 1 |
Krarup, AL | 1 |
Lottrup, C | 1 |
Masharova, AA | 1 |
Moawad, FJ | 1 |
Olesen, AE | 1 |
Riordan, J | 1 |
Murphy, P | 1 |
Pistoia, F | 1 |
Sacco, S | 1 |
Sarà, M | 1 |
Franceschini, M | 1 |
Carolei, A | 1 |
Beecham, E | 1 |
Candy, B | 1 |
Howard, R | 1 |
McCulloch, R | 1 |
Laddie, J | 1 |
Rees, H | 1 |
Vickerstaff, V | 1 |
Bluebond-Langner, M | 1 |
Jones, L | 1 |
Martins, I | 1 |
Carvalho, P | 1 |
de Vries, MG | 1 |
Teixeira-Pinto, A | 1 |
Wilson, SP | 1 |
Westerink, BHC | 1 |
Tavares, I | 1 |
Bagmetova, VV | 1 |
Krivitskaya, AN | 1 |
Tyurenkov, IN | 1 |
Huang, D | 1 |
Huang, S | 2 |
Peers, C | 1 |
Du, X | 1 |
Zhang, H | 1 |
Gamper, N | 1 |
Bassani, AS | 1 |
Banov, D | 1 |
McCormick, ZL | 1 |
Chu, SK | 1 |
Binler, D | 1 |
Neudorf, D | 1 |
Mathur, SN | 1 |
Lee, J | 1 |
Marciniak, C | 1 |
Zeman, A | 1 |
Hoefeijzers, S | 1 |
Milton, F | 1 |
Dewar, M | 1 |
Carr, M | 1 |
Streatfield, C | 1 |
Hoving, MA | 1 |
van Raak, EP | 1 |
Spincemaille, GH | 1 |
van Kranen-Mastenbroek, VH | 1 |
van Kleef, M | 1 |
Gorter, JW | 1 |
Vles, JS | 2 |
Brennan, PM | 1 |
Whittle, IR | 1 |
Kofler, M | 2 |
Quirbach, E | 1 |
Schauer, R | 1 |
Singer, M | 1 |
Saulino, M | 1 |
Burton, AW | 1 |
Danyo, DA | 1 |
Frost, S | 1 |
Glanzer, J | 1 |
Solanki, DR | 1 |
Landry, M | 1 |
Nagy, F | 1 |
Tambeli, CH | 1 |
Levine, JD | 1 |
Gear, RW | 1 |
Franek, M | 1 |
Vaculin, S | 1 |
van der Plas, AA | 1 |
van Rijn, MA | 1 |
van Hilten, JJ | 1 |
Teasell, RW | 1 |
Mehta, S | 1 |
Aubut, JA | 1 |
Foulon, B | 1 |
Wolfe, DL | 1 |
Hsieh, JT | 1 |
Townson, AF | 1 |
Short, C | 1 |
Silva, JR | 1 |
Silva, ML | 1 |
Prado, WA | 1 |
Wallace, MS | 1 |
Rauck, RL | 1 |
Deer, T | 1 |
Tomas, M | 1 |
Javier, N | 1 |
Liu, LS | 1 |
Shenoy, M | 1 |
Pasricha, PJ | 1 |
Ucar, T | 1 |
Kazan, S | 1 |
Turgut, U | 1 |
Samanci, NK | 1 |
Kumru, H | 1 |
Flores, MC | 1 |
Portell, E | 1 |
Robles, V | 1 |
Leon, N | 1 |
Vidal, J | 2 |
Solaro, C | 1 |
Trabucco, E | 1 |
Messmer Uccelli, M | 1 |
Deseure, K | 1 |
Koek, W | 1 |
Colpaert, FC | 1 |
Adriaensen, H | 1 |
Blednov, YA | 1 |
Stoffel, M | 1 |
Alva, H | 1 |
Harris, RA | 1 |
Dickerman, RD | 1 |
Stevens, QE | 1 |
Schneider, SJ | 1 |
Turner, MS | 1 |
Taira, T | 6 |
Hori, T | 3 |
McCleane, G | 1 |
Takeda, M | 1 |
Tanimoto, T | 1 |
Ikeda, M | 1 |
Kadoi, J | 1 |
Matsumoto, S | 1 |
Dang, K | 1 |
Bowery, NG | 2 |
Urban, L | 3 |
Liu, J | 1 |
Wolfe, D | 1 |
Hao, S | 1 |
Glorioso, JC | 1 |
Mata, M | 1 |
Fink, DJ | 1 |
Ben Smail, D | 1 |
Jacq, C | 1 |
Denys, P | 1 |
Bussel, B | 1 |
Naderi, N | 1 |
Shafaghi, B | 1 |
Khodayar, MJ | 1 |
Zarindast, MR | 1 |
Akada, Y | 1 |
Mori, R | 1 |
Kato, Y | 1 |
Yamasaki, F | 1 |
Mochizuki, H | 1 |
Guillaume, D | 1 |
Van Havenbergh, A | 1 |
Vloeberghs, M | 1 |
Roeste, G | 1 |
Potes, CS | 1 |
Neto, FL | 1 |
Castro-Lopes, JM | 1 |
Guglielmino, A | 1 |
Sorbello, M | 1 |
Fazzio, S | 1 |
Zingale, SF | 1 |
Bucolo, GE | 1 |
Pittalà, G | 1 |
Castiglione, A | 1 |
Patti, F | 1 |
Mangiameli, S | 1 |
Cooper, JA | 1 |
Ridley, B | 1 |
Al Khudhairi, D | 1 |
Rababa, A | 1 |
Saddiqui, MN | 1 |
LaGraize, SC | 1 |
Fuchs, PN | 1 |
Ochiai, T | 1 |
Goto, S | 1 |
Lind, G | 1 |
Schechtmann, G | 1 |
Winter, J | 1 |
Linderoth, B | 3 |
McClelland, S | 1 |
Bethoux, FA | 1 |
Boulis, NM | 1 |
Sutliff, MH | 1 |
Stough, DK | 1 |
Schwetz, KM | 1 |
Gogol, DM | 1 |
Harrison, M | 1 |
Pioro, EP | 1 |
Sadiq, SA | 1 |
Poopatana, CA | 1 |
Müller, H | 2 |
Fafara, A | 1 |
Kwiatkowski, S | 1 |
Kawecka, J | 1 |
Grzegorzewski, P | 1 |
Kawecki, Z | 1 |
Stevenson, VL | 1 |
Sawynok, J | 7 |
Tsai, HY | 2 |
Dickson, C | 1 |
Yaksh, TL | 2 |
Reddy, SV | 1 |
McLeod, JG | 1 |
Corli, O | 1 |
Roma, G | 1 |
Bacchini, M | 1 |
Battagliarin, G | 1 |
Di Piazza, D | 1 |
Brambilla, C | 1 |
Grossi, E | 1 |
Kirubakaran, V | 1 |
Mayfield, D | 1 |
Rengachary, S | 1 |
Kirchner, P | 1 |
Menon, MK | 1 |
Clark, WG | 1 |
Vivonia, C | 1 |
Rahman, AF | 1 |
Takahashi, M | 1 |
Kaneto, H | 1 |
Ocaña, M | 2 |
Del Pozo, E | 1 |
Barrios, M | 2 |
Olausson, B | 1 |
Xu, ZQ | 1 |
Shyu, BC | 1 |
Bennett, MI | 1 |
Tai, YMA | 1 |
Symonds, JM | 1 |
Anghinah, R | 1 |
Oliveira, AS | 1 |
Gabbai, AA | 1 |
Tanikawa, T | 3 |
Kawamura, H | 3 |
Iseki, H | 3 |
Takakura, K | 3 |
Sabbe, MB | 1 |
Grafe, MR | 1 |
Pfeifer, BL | 1 |
Mirzai, TH | 1 |
Sharma, R | 1 |
Mathur, R | 1 |
Nayar, U | 1 |
Suh, HW | 1 |
Song, DK | 1 |
Son, KH | 1 |
Woo, MH | 1 |
Do, JC | 1 |
Choi, YS | 1 |
Lee, KH | 1 |
Kim, YH | 1 |
Kawabatake, H | 2 |
Ueda, A | 1 |
Buritova, J | 1 |
Chapman, V | 1 |
Honoré, P | 1 |
Besson, JM | 1 |
Cui, JG | 2 |
Meyerson, BA | 2 |
Parise, M | 1 |
García-Larrea, L | 1 |
Mertens, P | 1 |
Sindou, M | 1 |
Mauguière, F | 1 |
Nguyen, TT | 1 |
Matsumoto, K | 1 |
Watanabe, H | 1 |
Canavero, S | 1 |
Bonicalzi, V | 1 |
Hammond, DL | 1 |
Nelson, V | 1 |
Thomas, DA | 1 |
Thompson, E | 1 |
Hicks, F | 1 |
Yakhnitsa, V | 1 |
Sollevi, A | 1 |
Segerdahl, M | 1 |
Stiller, CO | 1 |
O'Connor, WT | 1 |
Zarrindast, MR | 3 |
Rezayat, M | 2 |
Ghanipoor, N | 1 |
Parvini, S | 2 |
Tabarrai, E | 1 |
Pirali, M | 1 |
Wiesenfeld-Hallin, Z | 2 |
Aldskogius, H | 1 |
Grant, G | 1 |
Hao, JX | 2 |
Hökfelt, T | 1 |
Xu, XJ | 2 |
Ipponi, A | 1 |
Lamberti, C | 1 |
Medica, A | 1 |
Bartolini, A | 1 |
Malmberg-Aiello, P | 1 |
Fox, A | 2 |
Eastwood, C | 1 |
Manning, D | 1 |
Hara, K | 1 |
Saito, Y | 1 |
Kirihara, Y | 1 |
Yamada, Y | 1 |
Sakura, S | 1 |
Kosaka, Y | 1 |
Chiang, CY | 1 |
Kwan, CL | 1 |
Hu, JW | 1 |
Sessle, BJ | 1 |
Xu, IS | 1 |
Zuniga, RE | 1 |
Schlicht, CR | 1 |
Abram, SE | 1 |
Santos, Tde J | 1 |
de Castro-Costa, CM | 1 |
Giffoni, SD | 1 |
Santos, FJ | 1 |
Ramos, RS | 1 |
Gifoni, MA | 1 |
Iyadomi, M | 1 |
Iyadomi, I | 1 |
Kumamoto, E | 1 |
Tomokuni, K | 1 |
Yoshimura, M | 1 |
Becker, R | 2 |
Uhle, EI | 1 |
Alberti, O | 1 |
Bertalanffy, H | 2 |
Yajima, Y | 1 |
Narita, M | 1 |
Tsuda, M | 1 |
Imai, S | 1 |
Kamei, J | 1 |
Nagase, H | 1 |
Suzuki, T | 1 |
Riley, RC | 1 |
Trafton, JA | 1 |
Chi, SI | 1 |
Basbaum, AI | 1 |
Schuler, V | 1 |
Lüscher, C | 1 |
Blanchet, C | 1 |
Klix, N | 1 |
Sansig, G | 1 |
Klebs, K | 1 |
Schmutz, M | 1 |
Heid, J | 1 |
Spooren, W | 1 |
Jaton, AL | 1 |
Vigouret, J | 1 |
Pozza, M | 1 |
Kelly, PH | 1 |
Mosbacher, J | 1 |
Froestl, W | 1 |
Käslin, E | 1 |
Korn, R | 1 |
Bischoff, S | 1 |
Kaupmann, K | 1 |
van der Putten, H | 1 |
Bettler, B | 1 |
Dohi, S | 1 |
Mahmoudi, M | 1 |
de Louw, AJ | 1 |
de Vente, J | 1 |
Steinbusch, HP | 1 |
Steinbusch, HW | 1 |
Troost, J | 1 |
Schapiro, RT | 1 |
Gatscher, S | 1 |
Uhle, E | 1 |
Kadies, M | 1 |
Ollat, H | 1 |
Herman, RM | 1 |
D'Luzansky, SC | 1 |
Ippolito, R | 1 |
Serrano, I | 1 |
Ruiz, RM | 1 |
Serrano, JS | 1 |
Fernández, A | 1 |
Aley, KO | 2 |
Kulkarni, SK | 2 |
Guo, ZW | 1 |
Tu, SZ | 1 |
Li, WH | 1 |
Chen, J | 1 |
Steardo, L | 1 |
Robertson, G | 1 |
Hwang, AS | 1 |
Wilcox, GL | 1 |
Lin, JG | 1 |
Inoki, R | 1 |
Penn, RD | 1 |
Abelli, L | 1 |
Conte, B | 1 |
Somma, V | 1 |
Maggi, CA | 1 |
Giuliani, S | 1 |
Meli, A | 1 |
Baraldi, M | 1 |
Zanoli, P | 1 |
Benelli, A | 1 |
Sandrini, M | 1 |
Giberti, A | 1 |
Caselgrandi, E | 1 |
Tosi, G | 1 |
Preti, C | 1 |
Reid, A | 1 |
Zierski, J | 1 |
Dralle, D | 1 |
Wurdinger, T | 1 |
Panerai, AE | 1 |
Hormes, JT | 1 |
Benarroch, EE | 1 |
Rodriguez, M | 1 |
Klass, DW | 1 |
Pelley, KA | 1 |
Vaught, JL | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Randomized, Controlled, Open-label, Parallel-group, Multi-center Study to Compare the Effect of Intrathecal Baclofen Therapy Versus Best Medical Treatment on Severe Spasticity in Post-stroke Patients After 6 Months Active Treatment[NCT01032239] | Phase 4 | 61 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
Chronic Postsurgical Pain in Cerebral Palsy[NCT05764681] | 500 participants (Anticipated) | Observational | 2023-03-31 | Not yet recruiting | |||
Prospective, Cross Over Gabapentin vs Amitriptyline Study on Patients Suffering From Masticatory Muscle Pain[NCT02339662] | Phase 4 | 50 participants (Anticipated) | Interventional | 2015-02-28 | Recruiting | ||
Dexmedetomidine Comme Adjuvant à la rachianesthésie Lors de césariennes électives : Une étude Pilote[NCT05099055] | Phase 3 | 42 participants (Actual) | Interventional | 2022-03-15 | Completed | ||
Benefit of Acupuncture Combined to Regional Analgesia for Post Operative Pain Relief After Hysterectomy[NCT06002464] | 72 participants (Anticipated) | Interventional | 2023-09-01 | Recruiting | |||
The Use of Penile Vibratory Stimulation to Decrease Spasticity Following Spinal Cord Injury[NCT00223873] | 30 participants | Interventional | 2002-11-30 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Change in average 10MTWT from baseline to month 6 beetween ITB and BMT arm. Change=10MTWT at month 6 - 10MTWT at baseline (NCT01032239)
Timeframe: Baseline and month 6
Intervention | seconds (Mean) |
---|---|
ITB Therapy | 4.86 |
Best Medical Treatment (BMT) | -2.48 |
"AS is a manual test, measuring the resistance to passive movement about a joint with varying degrees of velocity. Scores range from 1-5, with 5 choices. A score of 1 indicates no resistance, and 5 indicates rigidity. The following muscle groups in the lower extremities were assessed: hip flexors, hip adductors, knee extensors, knee flexors, plantar flexors and ankle-dorsal flexors. Average AS was calculated as the average of AS scores of the 6 muscles of the affected lower extremity. Change in average AS in affected lower extremities from baseline to month 6 between ITB and BMT arm was assessed.~Change= AS at month 6 - AS at baseline." (NCT01032239)
Timeframe: Baseline and month 6
Intervention | units on a scale (Mean) |
---|---|
ITB Therapy | -0.99 |
Best Medical Treatment (BMT) | -0.43 |
"AS is a manual test, measuring the resistance to passive movement about a joint with varying degrees of velocity. Scores range from 1-5, with 5 choices. A score of 1 indicates no resistance, and 5 indicates rigidity. The following muscle groups in the upper extremities were assessed: wrist flexors, elbow flexors, elbow extensors, shoulder abductors and shoulder adductors. Average AS was calculated as the average of AS scores of the 5 muscles of the affected lower extremities. Change in average AS in affected upper extremities from baseline to month 6 between ITB and BMT arm was assessed.~Change= AS at month 6 - AS at baseline." (NCT01032239)
Timeframe: Baseline and month 6
Intervention | units on a scale (Mean) |
---|---|
ITB Therapy | -0.66 |
Best Medical Treatment (BMT) | -0.17 |
FIM contains 18 items composed of 13 motor tasks and 5 cognitive tasks. Tasks are rated on a 7-point ordinal scale that ranges from total assistance (or complete dependence) to complete independence. Ratings should reflect actual observed performance, not capability. Total score ranges from 18 (lowest) to 126 (highest) level of independence. Change in FIM total score from baseline to month 6 between ITB and BMT arm was assessed. Change=FIM score at month 6 - FIM score at baseline. (NCT01032239)
Timeframe: Baseline and month 6
Intervention | units on a scale (Mean) |
---|---|
ITB Therapy | 2.68 |
Best Medical Treatment (BMT) | -2.58 |
"SS-QoL questionnaire is a self-assessed quality of life questionnaire specifically designed for post-stroke patients. It evaluates 49 items across 12-domains: personality, energy, language, mobility, vision, upper extremity function, thinking, mood, work/productivity, self-care, and family and social roles. Each item is rated on a 5-point Likert Scale, measuring either positive or negative response to a statement. Summary score is composed of an unweighted average of the 12 domain scores, with higher scores indicating better QoL. Total score ranges from 1 to 5. Change in SS-QoL summary score from baseline to month 6 between ITB and BMT arm was assessed.~Change=SS-QoL score at month 6 - SS-QoL score at baseline." (NCT01032239)
Timeframe: Baseline and month 6
Intervention | units on a scale (Mean) |
---|---|
ITB Therapy | 0.26 |
Best Medical Treatment (BMT) | 0.05 |
"The EQ-5D-3L is a generic measure of health status consisting in the EQ-5D-3L descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-3L descriptive system is characterized on five dimensions: mobility, self-care, ability to undertake usual activities, pain and anxiety/depression. Patients were asked to indicate their level of health on each dimension using one of three levels: no health problems, moderate health problems, and severe health problems. Responses from the questionnaire were converted to a single health index utility score; this ranges from -0.595 to 1. EQ VAS records the patient's self-rated health on a vertical visual analogue scale from 0 to 100 where the endpoints are labelled 'Best imaginable health state' (100) and 'Worst imaginable health state' (0). Change in EQ-5D-3L utility score and VAS score from baseline to month 6 between ITB and BMT arm were assessed. Change=EQ-5D-3L utility or VAS score at month 6 - EQ-5D-3L utility or VAS score." (NCT01032239)
Timeframe: Baseline and month 6
Intervention | units on a scale (Mean) | |
---|---|---|
Utility Score | VAS | |
Best Medical Treatment (BMT) | 0.01 | 4.40 |
ITB Therapy | 0.09 | 9.68 |
"NPRS is designed to assess the level of pain a patient is feeling at a point in time. The following questions has been presented to patients: What is your actual spasticity-related or spasm-related pain? What was your least spasticity-related or spasm-related pain during the last week? What was your worst spasticity-related or spasm-related pain during the last week? The patient indicated how much pain he is feeling on a scale from 0 to 10. A score of 0 (zero) is no pain while a score of 10 (ten) is worst possible pain. Change in NPRS related to actual, least or worst pain from baseline to month 6 between ITB and BMT arm was assessed. Change=NPRS at month 6 - NPRS at baseline." (NCT01032239)
Timeframe: Baseline and month 6
Intervention | units on a scale (Mean) | ||
---|---|---|---|
Actual pain | Least Pain | Worst Pain | |
Best Medical Treatment (BMT) | 0.00 | 0.24 | -0.04 |
ITB Therapy | -1.17 | -1.61 | -1.35 |
The SF-12 is generic assessment of health-related quality of life, which evaluates 8 health dimensions (physical functioning, role physical, bodily pain, vitality, social functioning, role emotional, mental health, and general health). Subscale scores for each dimension were aggregated into summary scores for physical (PCS) and mental health (MCS) components (ranging from 0 to 100, with higher scores indicating better health). Changes in the PCS and MCS from baseline to Month 6 were both compared between the BMT and ITB arms. Change=SF-12 score at month 6 - SF-12 score at baseline. (NCT01032239)
Timeframe: Baseline and month 6
Intervention | units on a scale (Mean) | |
---|---|---|
PCS | MCS | |
Best Medical Treatment (BMT) | -1.13 | -0.82 |
ITB Therapy | 3.13 | 1.05 |
Number of patients with healthcare professional contacts outside of study visits in the ITB and BMT between baseline and months 6 (NCT01032239)
Timeframe: baseline, ITB test (only ITB arm), second assessment (only BMT arm), week 6 (only ITB arm), month 3, month 6
Intervention | Participants (Count of Participants) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Baseline : general practitioner | Baseline : neurologist | Baseline : nurse (hospital setting) | Baseline : nurse (home care) | Baseline : orthopedic surgeon | Baseline : other | ITB test:general practitioner | ITB test: neurologist | ITB test :other | Second Assessment: general practitioner | Second Assessment: neurologist | Second Assessment: nurse (home care) | Second Assessment: other | week 6: general practitioner | week 6: nurse (hospital setting) | week 6: other | month 3: general practitioner | month 3: neurologist | month 3: other | month 6: general practitioner | month 6: neurologist | month 6: other | |
Best Medical Treatment (BMT) | 8 | 8 | 0 | 1 | 0 | 13 | NA | NA | NA | 5 | 1 | 1 | 4 | NA | NA | NA | 8 | 3 | 9 | 7 | 2 | 11 |
ITB Therapy | 14 | 4 | 1 | 0 | 3 | 10 | 1 | 1 | 3 | NA | NA | NA | NA | 4 | 2 | 2 | 7 | 1 | 6 | 8 | 3 | 8 |
Patient was asked to transfer from the wheelchair to bed without human assistance. High level functional patient (HLP) could transfer. Low level functional patient (LLP) was not able to transfer. Comparison of the number and percentage of HLP and LLP between ITB and BMT arms was evaluated. (NCT01032239)
Timeframe: baseline, month 3, month 6
Intervention | Participants (Count of Participants) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Baseline72364475 | Baseline72364476 | Month 372364475 | Month 372364476 | Month 672364475 | Month 672364476 | |||||||
HLP | LLP | |||||||||||
ITB Therapy | 22 | |||||||||||
Best Medical Treatment (BMT) | 24 | |||||||||||
ITB Therapy | 9 | |||||||||||
Best Medical Treatment (BMT) | 21 | |||||||||||
ITB Therapy | 6 | |||||||||||
ITB Therapy | 19 | |||||||||||
Best Medical Treatment (BMT) | 19 | |||||||||||
ITB Therapy | 5 | |||||||||||
Best Medical Treatment (BMT) | 5 |
"Patients were presented with two statements (I am satisfied with the reduction in spasticity provided by my treatment, and I would recommend this therapy to a friend). They agreed, disagreed or were neutral with the statements." (NCT01032239)
Timeframe: month 6
Intervention | Participants (Count of Participants) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Patient Satisfaction with Spasticity Reduction72364475 | Patient Satisfaction with Spasticity Reduction72364476 | Patient Therapy Reccomandation72364475 | Patient Therapy Reccomandation72364476 | |||||||||
disagree | neutral | agree | ||||||||||
ITB Therapy | 2 | |||||||||||
Best Medical Treatment (BMT) | 7 | |||||||||||
ITB Therapy | 4 | |||||||||||
ITB Therapy | 16 | |||||||||||
Best Medical Treatment (BMT) | 11 | |||||||||||
Best Medical Treatment (BMT) | 5 | |||||||||||
ITB Therapy | 3 | |||||||||||
Best Medical Treatment (BMT) | 4 | |||||||||||
Best Medical Treatment (BMT) | 14 |
21 reviews available for baclofen and Ache
Article | Year |
---|---|
The case for cautious consumption: NSAIDs in chronic kidney disease.
Topics: Acute Kidney Injury; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Baclofen; Cost-Ben | 2019 |
Intrathecal baclofen: effects on spasticity, pain, and consciousness in disorders of consciousness and locked-in syndrome.
Topics: Baclofen; Consciousness; Consciousness Disorders; Drug Administration Schedule; Humans; Injections, | 2015 |
Pharmacological interventions for pain in children and adolescents with life-limiting conditions.
Topics: Adolescent; Alendronate; Baclofen; Botulinum Toxins, Type A; Cerebral Palsy; Child; Child, Preschool | 2015 |
Intrathecal baclofen therapy for neurological disorders: a sound knowledge base but many challenges remain.
Topics: Adult; Baclofen; Catheterization; Cerebral Palsy; Child; Child, Preschool; Dose-Response Relationshi | 2008 |
[GABA(B) receptors and sensitization to pain].
Topics: 14-3-3 Proteins; Allosteric Regulation; Animals; Baclofen; Calcium Channels; Calcium-Binding Protein | 2009 |
A systematic review of pharmacologic treatments of pain after spinal cord injury.
Topics: Analgesics; Anticonvulsants; Antidepressive Agents; Baclofen; Cannabinoids; Humans; Pain; Spinal Cor | 2010 |
Ziconotide combination intrathecal therapy: rationale and evidence.
Topics: Analgesics; Baclofen; Clonidine; Drug Therapy, Combination; Humans; Injections, Spinal; Morphine; om | 2010 |
Pain and multiple sclerosis: pathophysiology and treatment.
Topics: Analgesics, Opioid; Anticonvulsants; Antidepressive Agents; Baclofen; Cannabinoids; Fatigue; Humans; | 2013 |
Intrathecal drug delivery 2002.
Topics: Baclofen; Drug Approval; Humans; Infusion Pumps, Implantable; Injections, Spinal; Morphine; Movement | 2003 |
Clinical application of drug pump for spasticity, pain, and restorative neurosurgery: other clinical applications of intrathecal baclofen.
Topics: Baclofen; Cerebrovascular Circulation; Dystonia; Electric Stimulation Therapy; Humans; Infusion Pump | 2003 |
Pharmacological management of neuropathic pain.
Topics: Analgesics, Opioid; Anesthetics, Local; Anticonvulsants; Antidepressive Agents, Tricyclic; Baclofen; | 2003 |
GABAB receptor: a site of therapeutic benefit.
Topics: Animals; Baclofen; Brain; Clinical Trials as Topic; Cognition; Drug Evaluation, Preclinical; Epileps | 2006 |
Intrathecal baclofen in the treatment of post-stroke central pain, dystonia, and persistent vegetative state.
Topics: Baclofen; Dystonia; Humans; Muscle Relaxants, Central; Pain; Persistent Vegetative State; Stroke | 2007 |
Functional effects of spinal baclofen.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Baclofen; Child; Child, Preschool; Female; GABA Agonists | 2007 |
Relief of symptoms in end-stage neurological conditions.
Topics: Baclofen; Clinical Trials, Phase I as Topic; Cognition Disorders; Deglutition Disorders; Humans; Moo | 2007 |
The neurochemistry of central pain: evidence from clinical studies, hypothesis and therapeutic implications.
Topics: Anesthetics, Intravenous; Baclofen; Cerebral Cortex; GABA Agonists; gamma-Aminobutyric Acid; Glutami | 1998 |
[Non-opioid analgesics in cancer pain].
Topics: Adrenergic alpha-Agonists; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antide | 2001 |
Management of spasticity, pain, and paroxysmal phenomena in multiple sclerosis.
Topics: Acetates; Amines; Autoimmune Diseases; Baclofen; Benzodiazepines; Botulinum Toxins, Type A; Cannabin | 2001 |
The management of pain in spasticity.
Topics: Administration, Oral; Analgesics; Baclofen; Botulinum Toxins; Humans; Injections, Spinal; Muscle Rel | 2002 |
[Pharmacological treatment of neuropathic pain].
Topics: Anesthetics, Local; Anticonvulsants; Antidepressive Agents; Baclofen; Capsaicin; Chronic Disease; Di | 1992 |
Drug pumps for treatment of neurologic diseases and pain.
Topics: Alzheimer Disease; Baclofen; Bethanechol; Bethanechol Compounds; Catheters, Indwelling; Chronic Dise | 1985 |
13 trials available for baclofen and Ache
Article | Year |
---|---|
Attainment of personal goals in the first year of intrathecal baclofen treatment in dyskinetic cerebral palsy: a prospective cohort study.
Topics: Baclofen; Cerebral Palsy; Child; Cohort Studies; Dystonia; Goals; Humans; Injections, Spinal; Muscle | 2023 |
Ultrasound guidance versus landmark guidance for intrathecal baclofen pump refill: A randomized pilot study.
Topics: Adolescent; Baclofen; Humans; Pain; Pilot Projects; Ultrasonography; Ultrasonography, Interventional | 2023 |
Neuromodulation and quality of life for patient with spasticity after spinal cord injury.
Topics: Baclofen; Female; Humans; Male; Muscle Relaxants, Central; Muscle Spasticity; Pain; Quality of Life; | 2023 |
Effect of Intrathecal Baclofen on Pain and Quality of Life in Poststroke Spasticity.
Topics: Administration, Oral; Aged; Baclofen; Benzodiazepines; Clonidine; Dantrolene; Female; Humans; Infusi | 2018 |
Limitations of intrathecal baclofen for spastic hemiparesis following stroke.
Topics: Adolescent; Adult; Baclofen; Child; Dose-Response Relationship, Drug; Female; GABA Agonists; Gait Di | 2009 |
A clinical study of intrathecal baclofen using a programmable pump for intractable spasticity.
Topics: Adolescent; Adult; Aged; Baclofen; Child; Child, Preschool; Cognition; Female; Humans; Infusion Pump | 2005 |
Drug-enhanced spinal stimulation for pain: a new strategy.
Topics: Animals; Baclofen; Dose-Response Relationship, Drug; Electric Stimulation; Follow-Up Studies; GABA A | 2007 |
Intrathecal baclofen for spasticity-related pain in amyotrophic lateral sclerosis: efficacy and factors associated with pain relief.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Baclofen; Cohort Studies; Female; Humans; Infusion Pumps | 2008 |
Intrathecal baclofen and morphine in multiple sclerosis patients with severe pain and spasticity.
Topics: Adult; Baclofen; Drug Therapy, Combination; Female; Humans; Injections, Spinal; Male; Middle Aged; M | 2007 |
Double-blind placebo-controlled trial of baclofen, alone and in combination, in patients undergoing voluntary abortion.
Topics: Abortion, Induced; Adolescent; Adult; Baclofen; Clinical Trials as Topic; Diazepam; Dilatation and C | 1984 |
Spinal intrathecal baclofen suppresses central pain after a stroke.
Topics: Baclofen; Cerebrovascular Disorders; Female; Humans; Injections, Spinal; Male; Middle Aged; Pain; Pa | 1994 |
Intrathecal baclofen is analgesic in patients with chronic pain.
Topics: Aged; Amputation, Surgical; Baclofen; Cerebral Palsy; Chronic Disease; Female; GABA Agonists; Hemato | 2000 |
Intrathecal baclofen suppresses central pain in patients with spinal lesions. A pilot study.
Topics: Adult; Baclofen; Double-Blind Method; Female; Humans; Injections, Spinal; Male; Middle Aged; Pain; R | 1992 |
109 other studies available for baclofen and Ache
Article | Year |
---|---|
5-(4-Chlorophenyl)-5,6-dihydro-1,3-oxazepin-7(4H)-one derivatives as lipophilic cyclic analogues of baclofen: design, synthesis, and neuropharmacological evaluation.
Topics: Animals; Baclofen; Cognition Disorders; Cyclization; Dose-Response Relationship, Drug; Drug Design; | 2008 |
Antiallodynic and analgesic effects of maslinic acid, a pentacyclic triterpenoid from Olea europaea.
Topics: Analgesics; Animals; Capsaicin; gamma-Aminobutyric Acid; Hyperalgesia; Inflammation; Mice; Molecular | 2013 |
Intrathecal baclofen overdose mimicking brainstem death during deep brain stimulation surgery for pain.
Topics: Adult; Baclofen; Bradycardia; Brain Stem; Deep Brain Stimulation; Humans; Infusion Pumps, Implantabl | 2022 |
G protein βγ subunits inhibit TRPM3 ion channels in sensory neurons.
Topics: Analgesics, Opioid; Animals; Baclofen; Calcium; Capsaicin; CHO Cells; Cricetulus; Electrophysiology; | 2017 |
Intrathecal baclofen treatment an option in X-linked adrenoleukodystrophy.
Topics: Adrenoleukodystrophy; Baclofen; Child; Dystonia; Dystonic Disorders; Humans; Infusion Pumps, Implant | 2018 |
Intrathecal baclofen in dyskinetic cerebral palsy: effects on function and activity.
Topics: Baclofen; Cerebral Palsy; Child; Dystonia; Female; Humans; Injections, Spinal; Male; Motor Activity; | 2018 |
Intrathecal Baclofen Therapy for Painful Muscle Spasms in a Patient with Friedreich's Ataxia.
Topics: Aged; Baclofen; Female; Follow-Up Studies; Friedreich Ataxia; Humans; Injections, Spinal; Muscle Rel | 2018 |
Egad!
Topics: Aged; Baclofen; Colchicine; Diagnosis, Differential; Female; Gout; Hallux; Hospitalization; Humans; | 2019 |
Inherited Ataxia and Intrathecal Baclofen for the Treatment of Spasticity and Painful Spasms.
Topics: Adult; Aged; Baclofen; Female; Friedreich Ataxia; Humans; Injections, Spinal; Male; Middle Aged; Mus | 2019 |
Low-Dose Intrathecal Ziconotide for Spasticity From Primary Lateral Sclerosis: A Case Report.
Topics: Adult; Baclofen; Female; Humans; Injections, Spinal; Motor Neuron Disease; Muscle Spasticity; omega- | 2019 |
Investigating the Feasibility of a Modified Quantitative Sensory Testing Approach to Profile Sensory Function and Predict Pain Outcomes Following Intrathecal Baclofen Implant Surgery in Cerebral Palsy.
Topics: Adolescent; Adult; Baclofen; Cerebral Palsy; Child; Feasibility Studies; Female; Humans; Infusion Pu | 2020 |
Has the time come for using intrathecal baclofen in neuropathic pain?
Topics: Baclofen; Evoked Potentials; Female; Humans; Male; Pain; Pain Perception; Spinal Cord Injuries | 2013 |
Painful traumatic trigeminal neuropathy: an open study on the pharmacotherapeutic response to stepped treatment.
Topics: Amines; Amitriptyline; Analgesics; Analgesics, Non-Narcotic; Baclofen; Carbamazepine; Clinical Proto | 2014 |
Vulvodynia and proctodynia treated with topical baclofen 5 % and palmitoylethanolamide.
Topics: Administration, Topical; Adult; Amides; Anti-Inflammatory Agents, Non-Steroidal; Anus Diseases; Bacl | 2014 |
Pharmacokinetics and pharmacodynamics of intravenous baclofen in dogs: a preliminary study.
Topics: Animals; Area Under Curve; Baclofen; Biological Availability; Dogs; Dose-Response Relationship, Drug | 2014 |
Pharmacologic treatments for esophageal disorders.
Topics: Analgesics, Opioid; Animals; Baclofen; Enteric Nervous System; Esophageal Diseases; Gastroesophageal | 2014 |
Intrathecal Pump: An Abrupt Intermittent Pump Failure.
Topics: Adult; Baclofen; Equipment Failure; Humans; Infusion Pumps, Implantable; Injections, Spinal; Male; M | 2015 |
GABA acting on GABAB receptors located in a medullary pain facilitatory area enhances nociceptive behaviors evoked by intraplantar formalin injection.
Topics: Animals; Baclofen; Disease Models, Animal; Formaldehyde; GABA-B Receptor Agonists; GABA-B Receptor A | 2015 |
Effects of Phenibut and Citrocard on Non-Competitive and Competitive Behavior during Provoked Aggression in Animals.
Topics: Agonistic Behavior; Animal Communication; Animals; Avoidance Learning; Baclofen; Competitive Behavio | 2015 |
GABAB receptors inhibit low-voltage activated and high-voltage activated Ca(2+) channels in sensory neurons via distinct mechanisms.
Topics: Animals; Baclofen; Calcium Channels, L-Type; Calcium Channels, N-Type; Calcium Channels, T-Type; Dit | 2015 |
Evaluation of the Percutaneous Absorption of Ketamine HCl, Gabapentin, Clonidine HCl, and Baclofen, in Compounded Transdermal Pain Formulations, Using the Franz Finite Dose Model.
Topics: Administration, Cutaneous; Aged; Amines; Baclofen; Clonidine; Cyclohexanecarboxylic Acids; Drug Comp | 2016 |
Intrathecal Versus Oral Baclofen: A Matched Cohort Study of Spasticity, Pain, Sleep, Fatigue, and Quality of Life.
Topics: Baclofen; Cohort Studies; Cross-Sectional Studies; Female; Humans; Injections, Spinal; Male; Middle | 2016 |
The GABAB receptor agonist, baclofen, contributes to three distinct varieties of amnesia in the human brain - A detailed case report.
Topics: Amnesia; Analgesics; Baclofen; Female; Humans; Memory, Episodic; Memory, Short-Term; Middle Aged; Pa | 2016 |
Safety and one-year efficacy of intrathecal baclofen therapy in children with intractable spastic cerebral palsy.
Topics: Adolescent; Baclofen; Cerebral Palsy; Child; Female; Follow-Up Studies; Humans; Infusion Pumps, Impl | 2009 |
Intrathecal ziconotide and baclofen provide pain relief in seven patients with neuropathic pain and spasticity: case reports.
Topics: Adult; Baclofen; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Muscle Relaxants, Cen | 2009 |
Centralization of noxious stimulus-induced analgesia (NSIA) is related to activity at inhibitory synapses in the spinal cord.
Topics: Analgesics; Animals; Baclofen; Capsaicin; Drug Interactions; GABA Agonists; GABA Antagonists; GABA-B | 2009 |
Role of GABA(B) receptor agonist baclofen in acute pain modulation during the early postnatal period.
Topics: Acute Disease; Age Factors; Animals; Baclofen; Disease Models, Animal; Dose-Response Relationship, D | 2009 |
Baclofen-induced chorea in complex regional pain syndrome-related dystonia.
Topics: Baclofen; Chorea; Dystonia; Female; Humans; Male; Middle Aged; Muscle Relaxants, Central; Pain | 2010 |
Analgesia induced by 2- or 100-Hz electroacupuncture in the rat tail-flick test depends on the activation of different descending pain inhibitory mechanisms.
Topics: Adjuvants, Anesthesia; Adrenergic alpha-Antagonists; Analgesia; Anesthetics, Intravenous; Animals; A | 2011 |
Persistent non-cancer pain management in the older adult.
Topics: Aged, 80 and over; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Baclofen; Drug Thera | 2010 |
The analgesic effects of the GABAB receptor agonist, baclofen, in a rodent model of functional dyspepsia.
Topics: Analgesics; Animals; Baclofen; Disease Models, Animal; Dyspepsia; Electromyography; GABA-A Receptor | 2011 |
Outcomes of intrathecal baclofen (ITB) therapy in spacticity.
Topics: Adolescent; Adult; Baclofen; Child; Child, Preschool; Disability Evaluation; Female; Follow-Up Studi | 2011 |
Effect of intrathecal baclofen on evoked pain perception: an evoked potentials and quantitative thermal testing study.
Topics: Adolescent; Adult; Baclofen; Evoked Potentials; Female; Humans; Injections, Spinal; Male; Middle Age | 2013 |
The 5-HT(1A) receptor agonist F 13640 attenuates mechanical allodynia in a rat model of trigeminal neuropathic pain.
Topics: Aminopyridines; Animals; Baclofen; Behavior, Animal; Disease Models, Animal; Dose-Response Relations | 2002 |
A pervasive mechanism for analgesia: activation of GIRK2 channels.
Topics: Analgesia; Analgesics; Animals; Baclofen; Benzoxazines; Clonidine; Crosses, Genetic; Ethanol; Female | 2003 |
The role of surgical placement and pump orientation in intrathecal pump system failure: a technical report.
Topics: Analgesia, Epidural; Baclofen; Catheters, Indwelling; Cerebral Palsy; Child; Device Removal; Equipme | 2003 |
Activaton of GABAB receptor inhibits the excitability of rat small diameter trigeminal root ganglion neurons.
Topics: Animals; Baclofen; Cells, Cultured; GABA Agonists; GABA Antagonists; Membrane Potentials; Neurons; P | 2004 |
Interaction of gamma-aminobutyric acid receptor type B receptors and calcium channels in nociceptive transmission studied in the mouse hemisected spinal cord in vitro: withdrawal symptoms related to baclofen treatment.
Topics: Action Potentials; Afferent Pathways; Animals; Baclofen; Calcium Channel Blockers; Calcium Channels; | 2004 |
Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain.
Topics: Animals; Baclofen; Bicuculline; Calcitonin Gene-Related Peptide; gamma-Aminobutyric Acid; Ganglia, S | 2004 |
Intrathecal baclofen in the treatment of painful, disabling spasms in Friedreich's ataxia.
Topics: Adult; Baclofen; Electromyography; Friedreich Ataxia; Humans; Male; Muscle Relaxants, Central; Pain; | 2005 |
Interaction between gamma-aminobutyric acid GABAB and cannabinoid CB1 receptors in spinal pain pathways in rat.
Topics: Analysis of Variance; Animals; Baclofen; Cyclohexanols; Dose-Response Relationship, Drug; Drug Inter | 2005 |
Analgesic properties of the novel compound M43068 in rat models of acute and neuropathic pain.
Topics: Adrenergic alpha-Antagonists; Analgesics; Animals; Baclofen; Behavior, Animal; Disease Models, Anima | 2005 |
Inhibition of pain behavior by GABA(B) receptors in the thalamic ventrobasal complex: effect on normal rats subjected to the formalin test of nociception.
Topics: Acute Disease; Analgesics; Animals; Baclofen; Behavior, Animal; Chronic Disease; Disease Models, Ani | 2006 |
Continuous intrathecal baclofen administration by a fully implantable electronic pump for severe spasticity treatment: our experience.
Topics: Adult; Aged; Baclofen; Female; Humans; Infusion Pumps, Implantable; Injections, Spinal; Male; Middle | 2006 |
Response of intrathecal baclofen resistance to dose reduction.
Topics: Adult; Analgesics; Anticonvulsants; Baclofen; Dose-Response Relationship, Drug; Drug Resistance; Dru | 2006 |
Intrathecal baclofen for muscle spasticity and pain--two case reports.
Topics: Adult; Baclofen; Female; Humans; Infusion Pumps, Implantable; Injections, Spinal; Male; Middle Aged; | 2006 |
GABAA but not GABAB receptors in the rostral anterior cingulate cortex selectively modulate pain-induced escape/avoidance behavior.
Topics: Animals; Avoidance Learning; Baclofen; Bicuculline; Escape Reaction; GABA Agonists; GABA Antagonists | 2007 |
Fifteen year experience of intrathecal baclofen treatment in Japan.
Topics: Baclofen; Brain Injuries; Child; Humans; Injections, Spinal; Japan; Male; Muscle Relaxants, Central; | 2006 |
[The parents expectations after baclofen pump implantation in child with severe spasticity in physical rehabilitation and psychological aspects].
Topics: Activities of Daily Living; Adult; Baclofen; Cerebral Palsy; Child; Female; Follow-Up Studies; Hemip | 2007 |
GABAergic mechanisms in antinociception.
Topics: Alkynes; Aminocaproates; Aminooxyacetic Acid; Analgesics; Animals; Baclofen; Bicuculline; Central Ne | 1984 |
Effect of neuroactive peptides on labeled 5-hydroxytryptamine release from rat spinal cord.
Topics: Animals; Baclofen; beta-Endorphin; Endorphins; Enkephalin, Methionine; Male; Naloxone; Neuropeptides | 1984 |
D-Baclofen: is it an antagonist at baclofen receptors?
Topics: Analgesics; Animals; Baclofen; Injections, Intraperitoneal; Injections, Spinal; Male; Pain; Rats; Ra | 1984 |
Studies in the primate on the analgetic effects associated with intrathecal actions of opiates, alpha-adrenergic agonists and baclofen.
Topics: Adrenergic alpha-Agonists; Analgesia; Animals; Avoidance Learning; Baclofen; Behavior, Animal; Cats; | 1981 |
When drugs can help in multiple sclerosis.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Baclofen; Dantrolene; Diazepam; Humans; Immuno | 1980 |
Dyskinesia and psychosis in a patient following baclofen withdrawal.
Topics: Adult; Baclofen; Humans; Male; Movement Disorders; Muscle Spasticity; Pain; Paraplegia; Psychoses, S | 1984 |
Monoamines as mediators of the antinociceptive effect of baclofen.
Topics: alpha-Methyltyrosine; Analgesics; Animals; Baclofen; Biogenic Amines; Male; Methyltyrosines; Pain; R | 1983 |
[Tasks and problems of general medical care in certain groups of disorders. Patients with mixed (motor and sensory) paralyses--from a neurological viewpoint].
Topics: Baclofen; Demyelinating Diseases; Diazepam; Electrogalvanism, Intraoral; Exercise Therapy; Hemiplegi | 1982 |
Interaction between phencyclidine (PCP) and GABA-ergic drugs: clinical implications.
Topics: Aminooxyacetic Acid; Anesthesia; Animals; Baclofen; Dextroamphetamine; Diazepam; Drug Interactions; | 1980 |
Role of GABAergic systems in the development of morphine tolerance in formalin-treated mice.
Topics: Analgesics, Opioid; Animals; Baclofen; Bicuculline; Diazepam; Drug Tolerance; Flumazenil; Formaldehy | 1995 |
Subgroups among mu-opioid receptor agonists distinguished by ATP-sensitive K+ channel-acting drugs.
Topics: 4-Aminopyridine; Adenosine Triphosphate; Animals; Baclofen; Benzopyrans; Cromakalim; Female; Mice; N | 1995 |
Dorsal column inhibition of nociceptive thalamic cells mediated by gamma-aminobutyric acid mechanisms in the cat.
Topics: Afferent Pathways; Animals; Baclofen; Cats; Dental Pulp; Electric Stimulation; GABA-A Receptor Antag | 1994 |
Staphylococcal meningitis following Synchromed intrathecal pump implant: a case report.
Topics: Adolescent; Baclofen; Cerebral Palsy; Humans; Infusion Pumps, Implantable; Injections, Spinal; Male; | 1994 |
Effect of baclofen on pain in diabetic neuropathy.
Topics: Adult; Baclofen; Diabetic Neuropathies; Humans; Male; Middle Aged; Pain | 1994 |
Toxicology of baclofen continuously infused into the spinal intrathecal space of the dog.
Topics: Animal Nutritional Physiological Phenomena; Animals; Baclofen; Cardiovascular System; Defecation; Do | 1993 |
GABA B mediated analgesia in tonic pain in monkeys.
Topics: Analgesics; Animals; Baclofen; Dose-Response Relationship, Drug; Formaldehyde; Macaca mulatta; Male; | 1993 |
Antinociceptive effect of smilaxin B administered intracerebroventricularly in the mouse.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Animals; Baclofen; Cerebral Ventricles; Dizocilpine Maleate; G | 1996 |
A new approach to the control of central deafferentation pain--spinal intrathecal baclofen.
Topics: Afferent Pathways; Aged; Baclofen; Cerebrovascular Disorders; Dose-Response Relationship, Drug; Drug | 1995 |
The contribution of GABAB receptor-mediated events to inflammatory pain processing: carrageenan oedema and associated spinal c-Fos expression in the rat.
Topics: Animals; Baclofen; Carrageenan; Dose-Response Relationship, Drug; Edema; GABA Agonists; Gene Express | 1996 |
Cromakalim differentially enhances antinociception induced by agonists of alpha(2)adrenoceptors, gamma-aminobutyric acid(B), mu and kappa opioid receptors.
Topics: Animals; Baclofen; Benzopyrans; Cromakalim; Dose-Response Relationship, Drug; Female; Mice; Mice, In | 1996 |
Effects of spinal cord stimulation on touch-evoked allodynia involve GABAergic mechanisms. An experimental study in the mononeuropathic rat.
Topics: Animals; Baclofen; Electric Stimulation; GABA Agonists; GABA Antagonists; GABA-A Receptor Agonists; | 1996 |
A new approach to control central deafferentation pain: spinal intrathecal baclofen.
Topics: Afferent Pathways; Aged; Baclofen; Central Nervous System; Cerebrovascular Disorders; Female; GABA A | 1995 |
Clinical use of polysynaptic flexion reflexes in the management of spasticity with intrathecal baclofen.
Topics: Adult; Baclofen; Dose-Response Relationship, Drug; Female; Humans; Infusion Pumps; Injections, Spina | 1997 |
Involvement of supraspinal GABA-ergic systems in clonidine-induced antinociception in the tail-pinch test in mice.
Topics: Adrenergic alpha-2 Receptor Agonists; Analgesics; Animals; Baclofen; Bicuculline; Clonidine; GABA An | 1997 |
Intrathecal methysergide antagonizes the antinociception, but not the hyperalgesia produced by microinjection of baclofen in the ventromedial medulla of the rat.
Topics: Analgesics; Animals; Baclofen; GABA-B Receptor Antagonists; Hyperalgesia; Injections, Spinal; Male; | 1998 |
Intrathecal baclofen and homeopathy for the treatment of painful muscle spasms associated with malignant spinal cord compression.
Topics: Aged; Baclofen; Holistic Health; Homeopathy; Humans; Injections, Spinal; Male; Muscle Relaxants, Cen | 1998 |
Modulation of spinal pain mechanisms by spinal cord stimulation and the potential role of adjuvant pharmacotherapy.
Topics: Adenosine; Animals; Baclofen; Behavior, Animal; Chemotherapy, Adjuvant; Combined Modality Therapy; D | 1997 |
Interactions between antinociception induced by cholecystokinin antagonists and GABA agonists in the tail-flick test.
Topics: Animals; Baclofen; Benzodiazepinones; Devazepide; Dose-Response Relationship, Drug; Drug Interaction | 1998 |
Effects of CCK antagonists on GABA mechanism-induced antinociception in the formalin test.
Topics: Analgesics, Non-Narcotic; Analgesics, Opioid; Animals; Baclofen; Dose-Response Relationship, Drug; F | 1999 |
Central inhibitory dysfunctions: mechanisms and clinical implications.
Topics: Animals; Baclofen; Central Nervous System; Cholecystokinin; GABA Agonists; Hormone Antagonists; Indo | 1997 |
Tiagabine antinociception in rodents depends on GABA(B) receptor activation: parallel antinociception testing and medial thalamus GABA microdialysis.
Topics: Abdomen; Animals; Baclofen; Constriction, Pathologic; Dose-Response Relationship, Drug; Escape React | 1999 |
Critical evaluation of the streptozotocin model of painful diabetic neuropathy in the rat.
Topics: Animals; Baclofen; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Disease Models, Animal; H | 1999 |
The interaction of antinociceptive effects of morphine and GABA receptor agonists within the rat spinal cord.
Topics: Analgesics, Opioid; Animals; Baclofen; Colon; Dose-Response Relationship, Drug; Drug Interactions; D | 1999 |
Effects of GABA receptor antagonist on trigeminal caudalis nociceptive neurons in normal and neonatally capsaicin-treated rats.
Topics: Animals; Animals, Newborn; Baclofen; Bicuculline; Brain Mapping; Capsaicin; Functional Laterality; G | 1999 |
Effects of intrathecal morphine, clonidine and baclofen on allodynia after partial sciatic nerve injury in the rat.
Topics: Analgesics; Analgesics, Opioid; Animals; Baclofen; Clonidine; Cold Temperature; Dose-Response Relati | 1999 |
The effect of baclofen on spontaneous and evoked behavioural expression of experimental neuropathic chronic pain.
Topics: Animals; Baclofen; Behavior, Animal; Chronic Disease; GABA Agonists; Male; Naloxone; Narcotic Antago | 1999 |
Presynaptic inhibition by baclofen of miniature EPSCs and IPSCs in substantia gelatinosa neurons of the adult rat spinal dorsal horn.
Topics: Animals; Baclofen; Dose-Response Relationship, Drug; Electrophysiology; Evoked Potentials; Excitator | 2000 |
Continuous intrathecal baclofen infusion in the management of central deafferentation pain.
Topics: Baclofen; Female; GABA Agonists; Humans; Injections, Spinal; Middle Aged; Multiple Sclerosis, Chroni | 2000 |
Modulation of NMDA- and (+)TAN-67-induced nociception by GABA(B) receptors in the mouse spinal cord.
Topics: Analgesics; Animals; Baclofen; Dizocilpine Maleate; Dose-Response Relationship, Drug; Excitatory Ami | 2000 |
Presynaptic regulation of spinal cord tachykinin signaling via GABA(B) but not GABA(A) receptor activation.
Topics: Animals; Baclofen; Dose-Response Relationship, Drug; GABA-B Receptor Agonists; Male; Neurons; Nocice | 2001 |
Epilepsy, hyperalgesia, impaired memory, and loss of pre- and postsynaptic GABA(B) responses in mice lacking GABA(B(1)).
Topics: Animals; Animals, Newborn; Avoidance Learning; Baclofen; Body Temperature Regulation; Delta Rhythm; | 2001 |
GABA mechanisms and antinociception in mice with ligated sciatic nerve.
Topics: Animals; Baclofen; Bicuculline; Dose-Response Relationship, Drug; Drug Interactions; GABA Agonists; | 2001 |
Baclofen inhibits ANP-mediated cyclic GMP synthesis in the rat cervical spinal cord.
Topics: Aging; Animals; Atrial Natriuretic Factor; Baclofen; Cervical Vertebrae; Cyclic GMP; GABA Agonists; | 2002 |
Combined intrathecal baclofen and morphine infusion for the treatment of spasticity related pain and central deafferentiation pain.
Topics: Afferent Pathways; Analgesics, Opioid; Baclofen; Central Nervous System Diseases; Denervation; Drug | 2002 |
GABAergic and cholinergic mediation in the antinociceptive action of homotaurine.
Topics: Acetates; Acetic Acid; Analgesics; Animals; Baclofen; gamma-Aminobutyric Acid; Immersion; Male; Mice | 1992 |
Baclofen analgesia in mice: a GABAB-mediated response.
Topics: Analgesia; Animals; Baclofen; Female; GABA-A Receptor Antagonists; Male; Mice; Naloxone; Organophosp | 1991 |
[Studies of synthesis and structure-activity relationships of analogs of the muscle relaxant--baclofen].
Topics: Animals; Baclofen; Female; Male; Mice; Muscle Relaxation; Pain; Receptors, GABA-A; Sensory Threshold | 1990 |
Clonidine reverses methylxanthine-induced potentiation of baclofen antinociception.
Topics: 1-Methyl-3-isobutylxanthine; Animals; Baclofen; Clonidine; Drug Interactions; Male; Neural Pathways; | 1985 |
Desensitization to substance P following intrathecal injection. A technique for investigating the role of substance P in nociception.
Topics: Animals; Baclofen; Injections, Spinal; Male; Morphine; Pain; Rats; Rats, Inbred Strains; Sensory Thr | 1985 |
Intradermal hypertonic saline-induced behavior as a nociceptive test in mice.
Topics: Animals; Anti-Inflammatory Agents; Baclofen; Behavior, Animal; Dose-Response Relationship, Drug; Inj | 1986 |
Further evidence for possible analgesic mechanism of electroacupuncture: effects on neuropeptides and serotonergic neurons in rat spinal cord.
Topics: Acupuncture Therapy; Analgesia, Epidural; Animals; Baclofen; Electric Stimulation; Enkephalin, Methi | 1989 |
GABAergic agents-induced antinociceptive effect in mice.
Topics: Analgesics; Animals; Baclofen; Bicuculline; Female; gamma-Aminobutyric Acid; Male; Mice; Morphine; M | 1989 |
A method for studying pain arising from the urinary bladder in conscious, freely-moving rats.
Topics: Animals; Baclofen; Behavior, Animal; Consciousness; Female; Morphine; Nociceptors; Pain; Rats; Sensa | 1989 |
Baclofen activates two distinct receptors in the rat spinal cord and guinea pig ileum.
Topics: Amino Acids; Amino Acids, Neutral; Animals; Baclofen; Ileum; Male; Pain; Rats; Rats, Inbred Strains; | 1986 |
Neurobehavioral, neuroendocrine and neurochemical effects of zinc supplementation in rats.
Topics: Adrenocorticotropic Hormone; Animals; Baclofen; Behavior, Animal; beta-Endorphin; Brain; Diazepam; E | 1986 |
Role of ascending and descending noradrenergic pathways in the antinociceptive effect of baclofen and clonidine.
Topics: Afferent Pathways; Animals; Baclofen; Central Nervous System; Clonidine; Efferent Pathways; Hydroxyd | 1986 |
Implanted pump systems for treatment of spasticity.
Topics: Adolescent; Adult; Aged; Baclofen; Child; Child, Preschool; Drug Administration Schedule; Equipment | 1988 |
[Potentiation concept in pharmacology].
Topics: 5-Hydroxytryptophan; Animals; Baclofen; Clomipramine; Diazepam; Drug Synergism; Drug Therapy, Combin | 1988 |
Periodic sharp waves in baclofen-induced encephalopathy.
Topics: Baclofen; Brain Diseases; Electroencephalography; Female; Humans; Middle Aged; Muscular Diseases; Pa | 1988 |
An antinociceptive profile of kojic amine: an analogue of gamma-aminobutyric acid (GABA).
Topics: Animals; Atropine; Atropine Derivatives; Baclofen; gamma-Aminobutyric Acid; Isoxazoles; Male; Mice; | 1987 |